A phase 2/3, multicenter, randomized, double-blind, placebo-controlled, combined dose finding and cardiovascular outcome study t

A phase 2/3, multicenter, randomized, double-blind, placebo-controlled, combined dose finding and cardiovascular outcome study to investigate the efficacy and safety of CSL300 (clazakizumab) in subjects with end stage kidney disease undergoing dialysis.

Open

Protocol code: CSL300_2301
EudraCT code: No aplica
Research group: Nephrology and kidney transplantation
Service: Nephrology
Principal investigator: Ramos Terrades, Natalia
Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
Phase: Fase III